antibodies for adam10  (Proteintech)

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Figure Lengend Snippet: Protein levels of ADAM10 species and mRNA in AD brain samples. Non-dementia controls (NDC, n = 13) and AD extracts ( n = 16) from prefrontal cortex were resolved by SDS-PAGE/electrophoresis prior to western blot assay. Each individual ADAM10 immunoreactive band was quantified, and levels normalized using GAPDH. A Representative western blot of ADAM10 using the rabbit anti- C-terminal region monoclonal antibody (ab124695, Abcam) and GAPDH with monoclonal antibody (60004-1-Ig, Proteintech) ( B ) Densitometric quantification of ADAM10 immunoreactive bands assigned to immature (iADAM10) and C mature (mADAM10) species normalized with respect to GAPDH. D Ratio mADAM10/iADAM10 that represents the amount of mature species vs. immature. E Relative mRNA levels of ADAM10 in NDC vs. AD patients’ samples were analyzed by qRT-PCR. Transcript levels were calculated by the comparative 2 − ΔCt method with respect to GAPDH. The graphs represent mean ± SEM. Significant P < 0.05 values assayed by t-test are indicated

Article Snippet: Representative blots of CSF samples of non-AD control individuals with large age amplitude (the age of the subjects are shown on top) probed with ( A ) anti-ADAM10 polyclonal antibody to ectodomain region (OAGA02442, Aviva) and ( B ) ADAM17 antibody towards the ectodomain region (AF9301, R&D Systems).

Techniques: SDS Page, Electrophoresis, Western Blot, Quantitative RT-PCR

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Figure Lengend Snippet: Aβ affects ADAM10 levels, but not ADAM17, in SH-SY5Y-differentiated neurons. SH-SY5Y cell cultures were differentiated to neurons with 10 µM retinoic acid treatment and then treated with 3 µM of Aβ42 for 48 h. A Representative western blot of control ( C ) and Aβ-treated (Aβ42) cell samples that was resolved with the anti C-terminal ADAM10 antibody (ab124695, Abcam). B Densitometric quantification of immunoreactive bands of iADAM10 and C mADAM10 with respect to GAPDH. Values represent the percentage with respect to control. D Values of the ratio between mature vs. immature species of ADAM10 (mADAM10/iADAM10). E Representative western blot of ADAM17 species resolved with anti-ectodomain region ADAM17 antibody (AF9301, R&D Systems) and the respective quantifications of F iADAM17 and G mADAM17 immunoreactive bands normalized to the ubiquitous protein GAPDH. H Result of the ratio of mADAM17/iADAM17. The graphs represent mean ± SEM of n = 12 samples of 3 independent experiments. Significant P < 0.05 values assayed by t-test are indicated

Article Snippet: Representative blots of CSF samples of non-AD control individuals with large age amplitude (the age of the subjects are shown on top) probed with ( A ) anti-ADAM10 polyclonal antibody to ectodomain region (OAGA02442, Aviva) and ( B ) ADAM17 antibody towards the ectodomain region (AF9301, R&D Systems).

Techniques: Western Blot, Control

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Figure Lengend Snippet: ADAM10 and ADAM17 CSF levels are not altered with aging. Representative blots of CSF samples of non-AD control individuals with large age amplitude (the age of the subjects are shown on top) probed with ( A ) anti-ADAM10 polyclonal antibody to ectodomain region (OAGA02442, Aviva) and ( B ) ADAM17 antibody towards the ectodomain region (AF9301, R&D Systems). Correlations between the age and the levels of ADAM10 and ADAM17 species ( C ) iADAM10, ( D ) mADAM10, ( E ) sADAM10, ( F ) iADAM17, ( G ) mADAM17 and ( H ) sADAM17 were assayed. All graphs include their Spearman coefficient (r) and the P value. None of the ADAM10 species nor ADAM17 correlate with age. * Refers to unspecific bands

Article Snippet: Representative blots of CSF samples of non-AD control individuals with large age amplitude (the age of the subjects are shown on top) probed with ( A ) anti-ADAM10 polyclonal antibody to ectodomain region (OAGA02442, Aviva) and ( B ) ADAM17 antibody towards the ectodomain region (AF9301, R&D Systems).

Techniques: Control

Journal: Alzheimer's Research & Therapy

Article Title: Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer’s disease patients

doi: 10.1186/s13195-026-02007-6

Figure Lengend Snippet: Levels of ADAM10 and ADAM17 species in AD CSF samples. Analysis of CSF ADAM10 and ADAM17 in non-AD controls (NADC) and in AD patients. A Representative blot of CSF probed against anti-ADAM10 ectodomain antibody. Quantification of immunoreactive band values obtained from B iADAM10, C mADAM10 and D sADAM10. E Values of the ratio between mature vs immature species of ADAM10 (mADAM10/iADAM10). F Representative blot of CSF probed against ADAM17 and the quantifications of the immunoreactivity of the bands for G iADAM17, H mADAM17 and I sADAM17. J Result of the ratio mADAM10/iADAM10. The graphs represent mean ± SEM. Significant P < 0.05 values assayed by t-test are indicated. * Refers to unspecific bands

Article Snippet: Representative blots of CSF samples of non-AD control individuals with large age amplitude (the age of the subjects are shown on top) probed with ( A ) anti-ADAM10 polyclonal antibody to ectodomain region (OAGA02442, Aviva) and ( B ) ADAM17 antibody towards the ectodomain region (AF9301, R&D Systems).

Techniques:

Journal: Scientific Reports

Article Title: Chronic inflammation promotes gastric cancer progression via ADAM10-mediated cleavage of CX3CL1

doi: 10.1038/s41598-026-39743-6

Figure Lengend Snippet: ADAM10-mediated increased cleavage of CX3CL1 contributes to CI-promoted GC progression. ( A-C ) RT-qPCR and Western blot confirmed that CI increased the mRNA and protein expression of ADAM10 in tumor tissues( n = 3 per group). ( D ) Immunofluorescence assay suggested the increase of ADAM10 (Red) fluorescence intensity in tumor tissues. ( E-F ) Western blot confirmed that LPS increased the protein expression of ADAM10 in GC cell lines( n = 3 per group). ( G ) ELISA assay demonstrated that the ADAM10 antagonist GI254023X could attenuate the LPS-induced increase in soluble CX3CL1 levels in GC cells( n = 3 per group). ( H-N ) ADAM10 antagonist GI254023X inhibited LPS-promoted GC cells migration and invasion( n = 3 per group). ( O ) Schematic diagram shows the experimental protocol for determine the effect of ADAM10 inhibitor GI in suppressingsing CI-promoted tumor progression in mice( n = 5 per group). ( P-Q ) Left: Representative macroscopic images of tumors; Right: weight of tumors( n = 5 per group). ( R ) Concentration of CX3CL1 in the mice tumors detected by ELISA( n = 3 per group). Data are represented as mean ± SEM. For panel F, statistical significance was determined relative to the 0 µg/mL LPS group. For panels G , I , K , N , statistical significance was determined relative to the LPS group. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001(A, C: two-tailed unpaired Student’s t test; F , G , I , K , N , Q , R : one-way ANOVA with Dunnett’s multiple comparisons test).

Article Snippet: Blotting detection was performed using anti-ADAM10 antibody(Proteintech, 25900-1-AP) and anti-CX3CR1 antibody(Proteintech, 29819-1-AP), followed by incubation with appropriate HRP-conjugated secondary antibodies for 1 h at room temperature.

Techniques: Quantitative RT-PCR, Western Blot, Expressing, Immunofluorescence, Fluorescence, Enzyme-linked Immunosorbent Assay, Migration, Concentration Assay, Two Tailed Test

Journal: Scientific Reports

Article Title: Chronic inflammation promotes gastric cancer progression via ADAM10-mediated cleavage of CX3CL1

doi: 10.1038/s41598-026-39743-6

Figure Lengend Snippet: Graphical Abstract. CI induces the upregulation of ADAM10 expression in GC cells. Upregulated ADAM10 mediates the cleavage of membrane-bound CX3CL1 (mCX3CL1), thereby promoting the release of soluble CX3CL1 (sCX3CL1). The increased sCX3CL1 ultimately enhance GC cell proliferation and migration to accelerate tumor progression.

Article Snippet: Blotting detection was performed using anti-ADAM10 antibody(Proteintech, 25900-1-AP) and anti-CX3CR1 antibody(Proteintech, 29819-1-AP), followed by incubation with appropriate HRP-conjugated secondary antibodies for 1 h at room temperature.

Techniques: Expressing, Membrane, Migration